Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Adapts Drug Development Tool Procedures to Adopt Alzheimer’s Simulation Tool

This article was originally published in RPM Report

Executive Summary

FDA recently featured an Alzheimer’s Disease clinical trial simulation tool as another positive, but low-visibility, step toward improving the drug development pathway for the disease. The process for accepting the tool may be as important as the tool itself.

You may also be interested in...



Using FDA’s New Drug Development Tool: Start With Narrow Context Of Use

As FDA gains experience with its new Drug Development Tool qualification process, the agency has found that a narrowly defined patient population and condition-specific measures are preferable.

COPD Patient-Reported Outcome Questionnaire Is Early Example of FDA Drug Development Tool “Approval” Process

FDA finalizes the "qualification process for drug development tools." The topic won't get as much attention as Breakthrough Therapy or Accelerated Approval, but the head of the drug center thinks this is a very big deal. A COPD outcomes assessment is an early example of the process in action.

Defense-to-Offense: PhRMA Readies to Protect Government Markets

White House budget targeting biopharma with new cuts hits just as the Pharmaceutical Research & Manufacturers of America’s annual meeting gets under way.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS079720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel